Ultragenyx Pharmaceutical Inc.RARENASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +42.27% | +29.42% | +27.99% | +13.24% | +14.65% |
| Gross Profit Growth | +36.07% | +28.30% | +21.17% | +14.11% | +11.37% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +33.25% | +17.95% | +14.24% | +13.72% | +4.48% |
| Weighted Average Shares Diluted Growth | +33.25% | +17.95% | +14.24% | +13.72% | +4.48% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +17.71% | +65.96% | -1.41% | +17.44% | +20.62% |
| Inventory Growth | +36.26% | +32.49% | +28.20% | +15.85% | +20.46% |
| Asset Growth | +24.25% | +0.83% | +0.37% | -19.29% | -22.62% |
| Book Value per Share Growth | +720.71% | -21.41% | -9.98% | -69.24% | -97.47% |
| Debt Growth | -26.90% | -6.56% | -6.10% | -3.10% | +2432.53% |
| R&D Expense Growth | +8.18% | +16.95% | -7.12% | +2.00% | +27.10% |
| SG&A Expenses Growth | +7.25% | +7.37% | +12.33% | +7.50% | +7.80% |